Erythrocyte G Protein as a Novel Target for Malarial Chemotherapy

Sean C. Murphy¹,², Travis Harrison¹,², Heidi E. Hamm³, Jon W. Lomasney¹,⁴, Narla Mohandas⁵, Kasturi Haldar¹,²*

¹ Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America, ² Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America, ³ Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America, ⁴ Department of Molecular Pharmacology and Biological Chemistry, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America, ⁵ New York Blood Center, New York, New York, United States of America

Funding: This work was supported by an American Heart Association predoctoral fellowship (0315210Z to SCM), a Northwestern University presidential fellowship (to SCM), and National Institutes of Health grants (PO1 HL078826 to KH, JWL, and NM; AI39071 and HL079397 to KH; HL55591 and HL03961 to JWL; EY06062 and EY10291 to HEH; and DK32094 to NM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

Academic Editor: Geoffrey Pasvol, Imperial College, United Kingdom

Citation: Murphy SC, Harrison T, Hamm HE, Lomasney JW, Mohandas N, et al. (2006) Erythrocyte G protein as a novel target for malarial chemotherapy. PLoS Med 3(12): e528. doi:10.1371/journal.pmed.0030258

Received: May 9, 2006
Accepted: November 13, 2006
Published: December 26, 2006

Copyright: © 2006 Murphy et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABBREVIATIONS: ATP, adenosine 5'-triphosphate; β-AR, β-adrenergic receptor; Gs, guanine nucleotide regulatory protein Gs; Hct, hematocrit; IC50, 50% inhibitory concentration; IC90, 90% inhibitory concentration; LY, lucifer yellow; LY-D, lucifer yellow-dextran; MCH, mean corpuscular hemoglobin; MCV, mean corpuscular volume; MWCO, molecular weight cut-off; P. falciparum histidine-rich protein II; RDW, red cell distribution width; RPMI, RPMI-1640

Background

Malaria remains a serious health problem because resistance develops to all currently used drugs when their parasite targets mutate. Novel antimalarial drug targets are urgently needed to reduce global morbidity and mortality. Our prior results suggested that inhibiting erythrocyte Gs signaling blocked invasion by the human malaria parasite Plasmodium falciparum.

Methods and Findings

We investigated the erythrocyte guanine nucleotide regulatory protein Gs as a novel antimalarial target. Erythrocyte “ghosts” loaded with a Gs peptide designed to block Gs interaction with its receptors, were blocked in β-adrenergic agonist-induced signaling. This finding directly demonstrates that erythrocyte Gs is functional and that propranolol, an antagonist of G protein–coupled β-adrenergic receptors, dampens Gs activity in erythrocytes. We subsequently used the ghost system to directly link inhibition of host Gs to parasite entry. In addition, we discovered that ghosts loaded with the peptide were inhibited in intracellular parasite maturation. Propranolol also inhibited blood-stage parasite growth, as did other β2-antagonists. β-blocker growth inhibition appeared to be due to delay in the terminal schizont stage. When used in combination with existing antimalarials in cell culture, propranolol reduced the 50% and 90% inhibitory concentrations for existing drugs against P. falciparum by 5- to 10-fold and was also effective in reducing drug dose in animal models of infection.

Conclusions

Together these data establish that, in addition to invasion, erythrocyte G protein signaling is needed for intracellular parasite proliferation and thus may present a novel antimalarial target. The results provide proof of the concept that erythrocyte Gs antagonism offers a novel strategy to fight infection and that it has potential to be used to develop combination therapies with existing antimalarials.

The Editors’ Summary of this article follows the references.
Introduction

*Plasmodium falciparum* is a protozoan parasite that causes the most lethal form of malaria, a major human disease urgently in need of new targets for future antimalarial drugs. Targeting the blood stages of infection is particularly important since these stages are responsible for all of the symptoms and pathologies associated with the disease. Increased resistance to antimalarial drugs is inevitably linked to mutation of parasite targets and reflects the general problem of continual emergence of resistance to drugs developed against microbial targets. Indeed, the discovery of drugs and targets that minimize the likelihood of drug-resistant microorganisms was recognized as a Grand Challenge in Global Health [1]. One strategy is to target critical host determinants needed for infection.

During *P. falciparum* blood-stage infection, the extracellular merozoite adheres to erythrocytes, and invades and develops intracellularly, surrounded by a parasitophorous vacuolar membrane. Merozoites that do not invade die, and thus erythrocytic infection is critical for parasite proliferation. In contrast to most cells, mature erythrocytes do not possess active endocytic machinery. Thus, malarial invasion was long considered to be dependent mainly on parasite factors released from invasive organelles of merozoites (i.e., rhoptries, dense granules, micronemes) [2]. However, a recent study showed that components enriched in erythrocyte detergent-resistant membrane lipid rafts are also involved in invasion [3]. At least 25 erythrocyte proteins reside in lipid rafts, and 12 of these are recruited to the parasitophorous vacuolar membrane, including two well-studied signaling proteins: the β2-adrenergic receptor (β2-AR) and its associated heterotrimeric G protein, Gs ([4–7]; SCM and KH, personal communication).

Accordingly, Harrison and coworkers found that β-adrenergic receptor (β-AR) and adenosine-receptor agonists (isoproterenol and 5′-N-ethylcarboxamidoadenosine, respectively), stimulated malarial entry into erythrocytes, while the respective antagonists (propranolol and 8-β-sulphophenyltheophylline) reversed agonist-induced stimulation of entry [7]. However, *Plasmodium* is a eukaryote and shares many cellular mechanisms with its host. In addition, erythrocytes are terminally differentiated cells, their signaling mechanisms are not well understood, and direct evidence that erythrocyte G proteins are active is not available. Thus, the finding that a peptide designed to inhibit host Gs function by blocking its interaction with host G-protein–coupled receptors (GPCRs) reduced invasion was important to the idea that erythrocyte Gs signaling regulated malarial invasion, even though *P. falciparum* lacks conserved heterotrimeric G proteins [7]. However, the peptide does not enter uninfected erythrocytes, and hence there is no evidence that it blocks endogenous erythrocyte Gs signaling. Furthermore, invasion alone is not considered a strong target for antimalarials because it is rapid (occurring in minutes). Agents that block invasion have a narrow window in which to act on the parasite and hence may reduce parasitemia, but may fail to quickly eradicate the parasite. Whether host Gs is needed for intracellular parasite growth as well as invasion, and may thus present a target for antimalarials, was not known.

In this paper we describe the development of erythrocyte “ghosts” that are active in β-adrenergic signaling and which closely mimic normal erythrocytes in supporting *P. falciparum* growth in culture. We used this system to investigate cytoplasmic erythrocyte molecules important in erythrocyte function, malarial entry, and intracellular growth and to determine whether such host molecules may serve as useful targets for antimalarial drug development.

Methods

Materials

Gs, Gic, Gi, and Gq peptides were described previously [7], although Gs and Gi peptides were obtained from the Protein Chemistry Core at Baylor College of Medicine (Houston, Texas, United States). All peptides were lyophilized and resuspended in culture medium before being added to cell cultures. Adenosine 5′-triphosphate (ATP), guanosine 5′-triphosphate (GTP), 70-kDa fluorescein isothiocyanate (FITC)–dextran, rhodamine-dextran, and drugs were from Sigma (http://www.sigmaaldrich.com). Lucifer yellow (LY), lucifer yellow-dextran (LY-D), and antibodies specific for glutathione S-transferase (GST, A5800) and green fluorescent protein (GFP, A6455) were from Invitrogen (http://www.invitrogen.com). Other chemicals were reagent-grade products from standard sources.

Preparation of Erythrocyte Ghosts and Loading of Cargo

Non-outdated blood obtained from LifeSource (http://www.lifesource.org) or from consenting adult donors (Northwestern University Institutional Review Board approval number 1425–002) was washed and erythrocytes were resuspended to 50% hematocrit (Hct) in cold PBS-glucose containing 1 mM ATP and a variety of cargoes. FITC- or rhodamine-labeled 70-kDa dextran (final concentration 1.0–2.5 mg/ml) were used as surrogate loading markers when non-fluorescent cargoes were loaded. Samples were chilled on ice and dialyzed with stirring against ice-cold 5 mM K2HPO4 supplemented with 1 mM ATP (final pH 7.4) for 1 h at 4 °C in pre-wetted 3.5-kDa molecular weight cut-off (MWCO) Slide-a-lyzer dialysis cassettes (Pierce Biotechnology, http://www.piercenet.com). Lysis was performed in buffers ≤ 4 °C to prevent premature membrane rescaling. Lysis of erythrocytes by dialysis and simultaneous equilibration with cargo avoided high-speed centrifugation of membranes. Use of a 3.5-kDa MWCO dialysis membrane minimized loss of small proteinaceous components of the erythrocyte cytoplasm.

Lysed erythrocytes were removed from dialysis membranes at 4 °C and were combined with one-fifth by volume of concentrated rescaling buffer (475 mM KOAc, 25 mM Na2HPO4, 25 mM MgCl2, and 237.5 mM KCl [pH 7.0], stored at 25 °C, supplemented with 1.5 mM dithiothreitol [DTT], 1 mM ATP, and 5 mM GTP) and incubated for 1 h at 37 °C with rotating. The final ionic concentrations were 95 mM KOAc, 5 mM MgCl2, 5 mM Na2HPO4, 47.5 mM KCl, 0.3 mM DTT, 1 mM ATP, and 1 mM GTP. Potassium was favored in the rescaling buffer because intracellular potassium concentration is high in normal, intact cells and a potassium-rich environment is known to be preferred by malaria parasites [8]. ATP (1 mM) and GTP (1 mM) were added to maintain critical nucleotide pools. Resealed ghosts were washed three times in serum-free RPMI-1640 (RPMI) at room temperature and resuspended to 10%–50% Hct in RPMI containing 10% human serum (complete RPMI-1640 [cRPMI]). Ghosts pre-
pared in this manner could be centrifuged at low g forces (600 g), similar to normal erythrocytes. As indicated in Figure 1, they were used to evaluate hematological properties, signaling functions, and malarial infection. Reports indicate that released ghosts can be permeable to small molecules [9,10], so when small cargoes were used (<10 kDa), ghosts were continuously bathed with cargo during the assays. Single hematomas of normal and ghosted erythrocytes that provided mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and red cell distribution width (RDW) were obtained using an automated Coulter counter (Department of Pathology, Northwestern Memorial Hospital, Chicago, Illinois, United States).

Estimation of Protein and ATP Concentration

Protein concentrations were measured by bicinechonic acid assay (Pierce) or by Bradford assay (Bio-Rad, http://www.bio-rad.com). The concentrations of ATP in ghosts and in normal intact erythrocytes were measured using an ATP-determination kit (A22066, Invitrogen) according to the manufacturer’s instructions; for each reaction, 1–10 × 10^5 cells were used per sample.

Protease-Protection Assay

Ghosts (5 × 10^7 cells per reaction) loaded with 40 μM purified GST were incubated in a total volume of 100 μl of PBS; samples were treated with or without 100 μg/ml of proteinase K (Roche, http://www.roche.com) and/or 0.5% Triton X-100 (w/v). Samples were incubated for 30 min at 37 °C, before protease activity was stopped by adding phenylmethylsulfonyl fluoride (1 mM final, Invitrogen). Proteins from 1 × 10^7 cells were solubilized in SDS-PAGE sample buffer, before being separated by 12% acrylamide SDS-PAGE and immunoblotted with GST-specific antibodies, as previously described [4,5].

Flow Cytometry

Ghosts loaded or unloaded with 0.5 mg/ml of 70-kDa FITC-dextran were washed three times and resuspended to 1% Hct in PBS-glucose. FITC fluorescence was measured on the gated erythroid population using a FACS Caliber flow cytometer (Becton-Dickinson, http://www.bd.com).

Cyclic Adenosine Monophosphate Assays

Normal, intact erythrocytes or erythrocyte ghosts were incubated in cRPMI containing media alone, 10 μM isoproterenol, 10 μM propranolol-DL, or both drugs in combination, for 30 min at 37 °C in 24-well tissue-culture plates. Cells were subsequently washed twice in cold PBS-glucose. Cyclic adenosine monophosphate (cAMP) levels were measured from 2.5–5.0 × 10^8 normal erythrocytes or ghosts using a quantitative, colorimetric cAMP immunoassay kit (Assay Designs direct cAMP immunoassay kit 900–066, http://www.assaydesigns.com). Measured cAMP concentrations were multiplied by 8.5 to account for the dilution of 50-μl cell pellets into 0.1 M HCl lysis buffer. Data are expressed as pmol cAMP per 1 × 10^5 cells.

Parasite Culture

P. falciparum strains 3D7 and FCB were cultured and synchronized using standard techniques [11,12]. For protein export experiments, P. falciparum 3D7 expressing P. falciparum histidine-rich protein II (PfHRPII) fused to GFP was cultured as previously described [13].

Invasion and Growth Assays in Culture

Mature schizont-stage cultures were synchronized using standard Percoll density gradients. Uninfected ghosts were incubated in cRPMI at 2%–5% Hct with 1%–3% synchronized schizonts in 24-well plates under standard culture conditions; ghosts were loaded with fusion proteins or bathed in peptides as appropriate. When adrenergic-acting drugs were used, they were dissolved in serum-free RPMI at 100-fold final concentration. Peptides were prepared as described above. For invasion assays, Giemsa-stained thin blood smears were made at 0 and 12–18 h post-invasion to determine parasitemias. For morphological growth assays, ghosts or normal erythrocytes were combined with synchronized schizont-stage parasites and cultured as above; subsequent trophozoite- and schizont-stage growth and reinvasion was monitored by Giemsa-stained smears at 32, 44, and 64 h after invasion. To test the reinvasion of normal erythrocytes by malaria parasites in ghost cultures, parasites were cultured in either ghosts or normal erythrocytes for 60 h and then diluted into normal erythrocytes for an additional 50 h; cultures were fed with fresh cRPMI and assessed by Giemsa-stained blood smears daily.

Microscopy

Ghosts were evaluated for cell morphology and loading efficiency by light and fluorescence microscopy, respectively. Parasitemias were determined by counting Giemsa-stained thin blood smears; the counter was blinded to sample identities. In experiments with ghosts, parasitemias were corroborated by counting fluorescently labeled ghosts with Hoechst 33342-stained nuclei. Light microscopy and image collection were carried out using a Zeiss Axioskop upright microscope and Nuance spectral camera/un-mixing system (Cambridge Research and Instrumentation, http://www.cri-inc.com). Fluorescence microscopy and digital image collection were carried out using an Olympus IX inverted fluorescence microscope and a Photometrix cooled CCD camera (CH350/LCCD) driven by DeltaVision software (Applied Precision, http://www.api.com) as described [6].

Effect of β-Blockers on Growth of P. falciparum In Vitro Cultures

The inhibitory effects of adrenergic antagonists were measured using standard [3H]-hypoxanthine-incorporation assays [14]. The data were regressed to transition functions [15] using TableCurve 2D software (Systat, http://www.systat.com); the Lorentzian cumulative transition function was consistently the best-fit function. The effects of β-blocker-containing drug combinations on growth were tested using fixed-ratio drug-combination assays [16]. Briefly, propranolol, chloroquine, and/or artemisinin were serially diluted in 200 μl of RPMI and added to 96-well plates with 2 × 10^7 infected erythrocytes at 0.6% parasitemia, containing primarily mature parasites. Cultures were incubated for 24 h under standard conditions until reinvasion occurred. Following invasion, 0.5 μCi of [3H]-hypoxanthine (Amersham Biosciences, http://www.amershambiosciences.com) was added to each well, and samples were re-incubated for 18 h. Plates were harvested onto filters, dried, and assayed for [3H]-hypoxan-
thine. Individual 50% inhibitory concentration (IC\textsubscript{50}) values were determined for each drug singly, and those values were used to establish drug ratios used in combination studies. Combined IC\textsubscript{50} values were determined for each drug in combination at 1:0, 3:1, 1:1, 1:3, and 0:1 ratios. A fractional IC\textsubscript{50} value (IC\textsubscript{50} in combination/IC\textsubscript{50} alone) was calculated for each drug-combination ratio and used to plot isobolograms [17]. The fractional IC\textsubscript{50} values for each drug were added; a sum \(>1\) indicates synergism, \(<1\) indicates antagonism, and equal to \(1\) indicates additive effects.

Effect of Propranolol on Sorbitol Sensitivity of \textit{P. falciparum}-Infected Erythrocytes

Incubation of 0–4 h rings at 10% parasitemia was performed in 0.75 ml of 2 or 10 \(\mu\)M propranolol in cRPMI, or in absence of the drug, for 30 h in 24-well plates; drug and media were refreshed after 15 h. The contents of each well were washed once in PBS-glucose and resuspended in 0.75 ml of 5% sorbitol for 15 min at 37 °C (cells were gently resuspended every 5 min throughout the incubation). At 0 and 15 min, 0.25-ml samples were removed, centrifuged for 5 min at 600 \(g\), and 0.15 ml of the supernatant was transferred to a well in a 96-well plate to measure hemoglobin release by spectrophotometric absorbance at 570 nm. The remainder of the sample (0.25 ml) was lysed by addition of 5 \(\mu\)l of 10% saponin (\(w/v\)), and the absorbance of total hemoglobin released was measured at 570 nm.

Effect of Propranolol on Protein Export in \textit{P. falciparum}-Infected Erythrocytes

Ring-stage cultures (10% parasitemia) of \textit{P. falciparum} 3D7 expressing PFHRPII-GFP [13] were treated with propranolol as described above for sorbitol assays. Drug-treated cultures were grown for an additional 30 h, transferred to tubes and washed twice with PBS-glucose. Cells were imaged live by digitized fluorescence microscopy to visualize export of the tagged transgene to the infected erythrocytes [13]. Protein export to the erythrocyte was quantified from 200 optical sections using previously described methods [18].

Effect of Propranolol/Chloroquine Drug Combination in a \textit{P. berghei} Infection of Mice

Mouse experiments were performed with BALB/c mice and \textit{P. berghei} ANKA strain using a standard 4-d Peter’s test [19]. The IC\textsubscript{50} of propranolol had been found previously to be \(~8\) mg/kg/d [7]; the IC\textsubscript{50} of chloroquine in a chloroquine-sensitive \textit{P. berghei} strain is \(~1.3–1.7\) mg/kg/d [19]. Mice received \(1 \times 10^7\) parasites intraperitoneally on day 0, followed by daily (chloroquine) and/or twice daily (propranolol) intraperitoneal drug treatments on days 0–3. Treatment groups were: control; chloroquine alone; propranolol alone; 2:1 propranolol:chloroquine; 1:1 propranolol:chloroquine; and 1:2 propranolol:chloroquine. Each group consisted of five different treatment doses with five mice per treatment dose; the control group contained five mice. Individual IC\textsubscript{50} values were previously determined for each drug singly, and those values were used to establish the drug ratios used in subsequent studies. The range of chloroquine doses was \(0.5–7.0\) mg/kg/d; the range of propranolol doses was \(1–96\) mg/kg/d. Blood smears were obtained by tail bleeding on day 4, and animals were sacrificed. Combined and fractional IC\textsubscript{50} values were determined for the indicated ratios, and an isobologram was plotted as for the in vitro results.

Statistics

Results represent the mean ± standard deviation unless otherwise stated. All experiments were performed in triplicate unless stated otherwise. Where indicated, representative data from individual experiments are shown. Statistical significance was determined using the Student’s \(t\)-test.

Results

Production of Ghosts with \(G_s\) Signaling and Malarial Infection that Closely Mimic Normal Erythrocytes

As summarized in Methods and in Figure 1, ghosts were prepared by dialysis of erythrocytes in a low MWCO membrane, simultaneously equilibrated with cargo and then resealed in a potassium-rich buffer in the presence of ATP (1...
mM) and GTP (1 mM), and finally washed successively in RPMI and cRPMI and used as described below. Non-outdated blood was used to make erythrocyte ghosts; freshly drawn erythrocytes were used for cAMP and malarial infection assays. These resealed ghosts morphologically resembled normal biconcave erythrocytes (Figure 2A). Early reports suggested that "white" ghosts depleted of hemoglobin remain permeable to small molecules [9,10]. However, ghosts prepared by our procedure contained 40%–50% of starting hemoglobin and maintained the millimolar levels of ATP in which they were prepared, indicating that, at a minimum, they retained critical energy pools. These levels were half of those measured in intact erythrocytes (Figure 2B), but within the range of ATP levels reported for erythrocytes [20,21]. Clinical hematogram analysis of a ghost preparation suggested that they contained less hemoglobin (lower MCH), were slightly microcytic (lower MCV), and were more heterogeneous (higher RDW) than normal, intact erythrocytes (Figure 2B). The ghosts could be efficiently and homogeneously loaded with a variety of experimental cargoes, such as high molecular weight rhodamine-labeled antibody (Figure 2C), as well as with smaller cargoes (not shown) such as low molecular weight LY (457 g/mol), 11-residue FITC-labeled Gs and Gscr peptides, 10-kDa LY-D, and 70-kDa FITC-dextran. Analyses of ghosts loaded with 70-kDa FITC-dextran by flow cytometry indicated that 99% of all cells were homogenously loaded with cargo (Figure 2D). Further tests of loading and retention of purified GST suggested that proteinaceous cargoes at 10–20 µM could be reliably encapsulated within ghosts and retained under culture conditions; this GST was resistant to degradation by exogenous protease (Figure 2E). These results indicated that ghosts stably maintain nucleotide pools and loaded cargoes.

One of our major interests in developing reconstituted erythrocyte ghosts was to study β-adrenergic signaling and its regulation by Gs. This investigation required the presence of active β-adrenergic signaling in ghosts. As shown in Figure 2F and 2G, cAMP production stimulated in ghosts by 10 µM isoproterenol (iso) was 9.00 pmol cAMP (95% CI 7.37–10.62 pmol) per 1 × 10⁸ cells. cAMP production in ghosts was measured and depicted as described in (F). Error bars show 95% CI of triplicate measurements in a representative experiment.

**Figure 2.** Hematological and Signaling Characteristics and Cargo Loading of Erythrocyte Ghosts

(A) Ghosts (left) were biconcave but retained less pigment than intact erythrocytes (right); bar represents 10 µm.

(B) Ghost MCH (normal range for erythrocytes 27.5–33.5 pg/cell), MCV (normal range for erythrocytes 80–100 fl), and RDW (normal range for erythrocytes 11.0%–15.0%) were determined using a Coulter counter (see Methods). Intracellular ATP levels were determined by luciferase-based ATP assays (see Methods); the 95% confidence interval (CI) for ATP levels is indicated; two experiments.

(C) Ghosts loaded with high molecular weight rhodamine-labeled antibody were imaged without fixation by fluorescence microscopy; bar represents 25 µm.

(D) Flow cytometry of unloaded (white fill) and FITC-dextran–loaded ghosts (green fill) 2 h post-resealing, showed homogenous loading of cargo. For each cell type, 100,000 gated events were captured.

(E) Western blot of GST-loaded ghosts after incubation in culture for 24 h and subsequent treatment in the presence or absence of proteinase K (Prot K) and/or Triton X-100 (TX100); see Methods. GST was detected by GST-specific immunoblotting.

(F) cAMP production in normal, intact erythrocytes treated with isoproprenol (iso) and/or propranolol (prop) as measured by enzyme-linked immunosorbent assay (see Methods). Error bars show 95% CI of triplicate measurements in a representative experiment. The mean baseline cAMP concentration in control erythrocytes was 0.61 pmol cAMP (95% CI 0.20–1.01 pmol; three experiments) per 1 × 10⁸ cells. Induced cAMP levels can vary—the maximal value obtained (once) was 14.58 pmol cAMP (95% CI 13.11–16.03 pmol) per 1 × 10⁸ cells.

(G) cAMP production in ghosts measured and depicted as described in (F). Error bars show 95% CI of triplicate measurements in a representative experiment. The mean baseline cAMP concentration in control ghosts was 1.12 pmol cAMP (95% CI 0.59–1.64 pmol; three experiments) per 1 × 10⁸ cells. The maximal isoproterenol-induced value obtained in a single ghost cAMP assay was 9.00 pmol cAMP (95% CI 7.37–10.62 pmol) per 1 × 10⁸ cells.

 doi:10.1371/journal.pmed.0030528.g002
isoproterenol (an agonist of β-ARs) was comparable to that seen in normal erythrocytes. This stimulation was quenched by the addition of equimolar racemic propranolol (the antagonist) in both cell types. Propranolol alone did not reduce basal cAMP levels in either cell type. The basal and isoproterenol-stimulated cAMP levels were similar to those previously measured in erythrocytes [22,23]. These data show that the β-adrenergic signaling pathway is active in these ghosts.

As we were also interested in testing the effects of signaling on malarial infection in ghosts, we next characterized ghosts for their ability to support malarial infection. The intra-erythrocytic lifecycle of malaria begins when extracellular merozoites rapidly (<2 min) invade mature erythrocytes. Intracellular ring-stage parasites result and subsequently enlarge into trophozoites. Schizogony follows when an average of 16 daughter parasites assemble and finally lyse out of infected cells to invade new erythrocytes. Therefore, ring formation provides a measurement of invasion and early development, while the appearance of trophozoites and schizonts indicates parasite maturation within the erythrocyte. In P. falciparum, this intracellular cycle lasts 48 h.

As shown, the resealed ghosts were infected by P. falciparum (Figure 3A). Remarkably, infection occurred with the same efficiency as in normal erythrocytes, and ghosts supported normal parasite maturation at both low and high parasitemias (Figure 3B). In cultures containing equal numbers of ghosts and normal erythrocytes, no preference was observed for invasion or growth in either cell type (Figure 3C).

Furthermore, parasites in ghost cultures appeared morphologically similar to their counterparts in normal erythrocytes at the three distinct ring, trophozoite, and schizont stages (Figure 3D). Schizonts that mature in ghosts are capable of rupturing and reinvasing ghosts (Figure 3E). Furthermore, parasites grown in either ghosts or normal erythrocytes when sub-cultured into normal erythrocytes showed no difference in growth over the next infective cycle (Figure 3E). Over three life cycles, completion of maturation of parasites in ghosts can extend from 48 to 54 h per cycle (unpublished data). We do not know why this occurs, but it is within an acceptable range of the asexual life cycle in normal P. falciparum cultures.

Collectively, these data show that erythrocyte ghosts, active in supporting β-adrenergic signaling and malarial invasion and growth, can be produced and stably loaded with exogenous cargo. Remarkably, the ghosts are essentially equivalent to normal erythrocytes in a number of critical respects, suggesting they may be useful for investigating multiple functions of the human erythrocyte and its infection by malaria parasites.

**Targeting Erythrocyte Gs**

Our previous studies had shown that a peptide designed to inhibit Gs protein interaction with its receptors blocked malarial entry into erythrocytes [7]. However, since the peptide does not diffuse into normal erythrocytes, there was no evidence that it blocked endogenous Gs function in...
the red cell. In addition, erythrocytes are terminally differentiated cells, their signaling mechanisms are not well understood, and direct evidence that erythrocyte G proteins are active is not available. We therefore introduced the Gs peptides into ghosts to establish whether it acted on its designated target Gs. As shown in Figure 4A, Gs peptide blocked cAMP production in response to the β-AR agonist, isoproterenol. The extent of this inhibition was comparable to that seen with propranolol, a β-adrenergic antagonist that blocks Gs signaling. This inhibitory effect was achieved at 40 µM Gs peptide, which is known to be effective at 10–50 nM in other cell types [24]. In contrast, the control scrambled peptide (Gscr) had no effect on cAMP production stimulated by isoproterenol. These data establish that β-adrenergic signaling in erythrocytes is mediated through Gs and that the Gs peptide directly targets and blocks activation of erythrocyte Gs.

To directly link this inhibition of host Gs to malarial infection, we assayed the effect of the peptide on parasite invasion and intracellular maturation in ghosts. As shown in Figure 4B, Gs peptide blocked malarial invasion at low micromolar concentrations. Importantly, there was a marked reduction in invasion at the same peptide concentration (40 µM) that blocked Gs activation. In contrast, control Gscr peptide had no effect on parasite invasion into ghosts, even at a higher concentration (up to 400 µM, Figure 4B). In addition, peptides designed to block Gi or Gq proteins also had no effect on invasion (Figure S1). These data establish that the Gs peptide can block malarial entry at the same concentrations that quench receptor-mediated Gs signaling. However, invasion is not completely abolished, suggesting that there may be additional mechanisms that regulate entry. Thus, if Gs only regulates invasion, it may not provide a satisfactory target for development of antimalarials.

Our results presented in Figure 3 suggest that ghosts support normal invasion and intracellular development of parasites, and thus allow us to examine erythrocyte functions needed in malarial entry as well as intracellular growth. To determine the requirement of Gs signaling for intraerythrocytic parasite growth, we followed the development of rings formed in the presence of 40 µM peptide to schizogony. As shown in Figure 4C, at this concentration of peptide, there was no measurable effect on trophozoites formed, but the number of schizonts detected was reduced. Since maturing trophozoites are known to actively ingest as much as 80% of the erythrocyte cytoplasm, the net intraerythrocytic peptide concentration at schizont stages of growth may be lower. Nonetheless, the data presented in Figure 4B and 4C provide a pharmacological link between the inhibition of host erythrocyte signaling, malaria parasite invasion, and intra-erythrocytic development.

A second, independent way of down-regulating Gs signaling in erythrocytes is by using β-antagonists. The β-blocker propranolol was previously known to inhibit isoproterenol-
mediated stimulation of invasion at \textasciitilde 10 \textmu M [7], but effects on \textit{P. falciparum} intracellular maturation and growth were not studied. In standard growth assays, we found that propranolol inhibited \textsuperscript{3}H-labeled hypoxanthine uptake by half (IC\textsubscript{50}) at 1.2 \textmu M and by 90\% inhibitory concentration (IC\textsubscript{90}) at 7.1 \textmu M (Figure 5A). Since hypoxanthine incorporation is a standard measure of parasite proliferation, the data confirm that, in addition to invasion, propranolol can block one or more processes needed for intracellular parasite survival. The inactive isomer of propranolol was not inhibitory, suggesting that the antimalarial effect of racemic propranolol is due to specific down-regulation of erythrocyte G\textsubscript{s} signaling. Examination of Giemsa-stained slides from treated cultures (Figure 5B) showed that 2 \textmu M propranolol blocked intracellular maturation of parasites to the schizont stage. At 2 \textmu M, propranolol had no significant effect on invasion, which is consistent with our earlier data indicating that significant inhibition of invasion required \textasciitilde 10 \textmu M drug [7]. Hence, the observed IC\textsubscript{50} of 1.2 \textmu M suggests that most of the inhibitory activity of propranolol is due to blockage of intracellular parasite maturation. Other \beta\_antagonists such as ICI118,551 and alprenolol also blocked parasite growth, as measured by hypoxanthine incorporation (Figure 5C). One \beta\_\beta\_antagonist, nadolol, was ineffective at 10 \textmu M. All three \beta\_specific antagonists had no effect, and this may reflect a lack of \beta\_adrenergic receptors on the erythrocyte. The three most active \beta-antagonists (including propranolol) appear to show IC\textsubscript{50} values of between 1 and 10 \textmu M. Testing additional \beta-antagonists (particularly \beta\_antagonists) may yield additional active inhibitors.

To examine intraerythrocytic process(es) that may be inhibited by propranolol treatment, we tested several general functions of malaria parasites. First, we tested the sensitivity of control and propranolol-treated parasites to lysis in the presence of 5\% sorbitol, which is known to be actively imported into trophozoite- and schizont-stage parasites—likely via the plasmodial nutrient transport channel PESAC [25]. No difference was found between control and drug-treated parasites (Figure 5A), suggesting that maturation to the trophozoite stage occurred in both 2 and 10 \textmu M propranolol-treated infected cells. Second, export of a parasite-encoded protein PfHRPII fused to GFP to the erythrocyte [13] was not blocked by either 2 or 10 \textmu M propranolol (Figure 6B), suggesting that the drug did not act by altering protein export to host cells. Nonetheless, examination of the morphology of 2 \textmu M propranolol-treated parasites per 1000 erythrocytes (std. dev.)

Figure 5. \beta-Blockers Inhibit Maturation of \textit{P. falciparum} in In Vitro Cultures

(A) \textsuperscript{3}H-hypoxanthine incorporation of \textit{P. falciparum} 3D7 when treated with racemic propranolol (indicated by black diamonds) or its inactive isomer (indicated by grey squares). Error bars show the standard deviation of triplicate measurements. IC\textsubscript{50} values were determined by fitting the data as described in Methods; the IC\textsubscript{50} value obtained for racemic propranolol (1.2 \textmu M; 95\% CI 1.0–1.6 \textmu M) is shown. Three experiments; hatched sign indicates \textit{p} < 0.001; asterisks indicate \textit{p} < 0.03 compared to equimolar inactive propranolol.

(B) Effect of 2 \textmu M propranolol on intracellular growth in normal erythrocytes. Mock- and drug-treated cultures were monitored at 15, 32, and 44 h after invasion by examination of Giemsa-stained thin blood smears. The number of ring (R)–, trophozoite (T)–, and schizont (S)–stage parasites per 1000 total erythrocytes at each time point are shown; numbers in parentheses indicate the standard deviation of triplicate measurements from one experiment; the total number of experiments was three.

(C) \textsuperscript{3}H-hypoxanthine incorporation of \textit{P. falciparum} 3D7–infected erythrocytes treated with 1 or 10 \textmu M concentrations of adrenergic-acting drugs (nonspecific \beta\_\beta\_–antagonists: propranolol, alprenolol, and nadolol; \beta\_specific antagonists: ICI118,551 and butoxamine; \beta\_specific antagonists: acebutalol, atenolol, and metoprolol; and \alpha\_specific agonist [ag]: clonidine). Chloroquine (50 nM) was used as an inhibitory control. Triplicate samples; asterisks denote a treatment with \textit{p} < 0.001 compared to control-treated cultures.

\textit{doi}:10.1371/journal.pmed.0030528.g005

\textit{Erythrocyte G\textsubscript{s} and Malarial Infection}
parasites at 44 h post-invasion (Figure 6C) revealed a lack of the segmented, mature schizonts characteristically found in control cultures at 44 h. Control cultures also showed the presence of new rings (marked by an asterisk in Figure 5B) indicating their acceleration past segmented schizonts to new rings. (This variation of the 48-h intraerythrocytic cycle is frequently observed in culture.) The effect of propranolol on parasite morphology was greater at 10 µM (compared to 2 µM), but the precise nature of one or more steps regulated by Gs signaling and needed for maturation to the schizont stage remains unknown.

Inhibitors of Erythrocyte Gs Signaling May Be Useful as Novel Antimalarial Therapeutics

The emergence of drug-resistant parasites has led to the need for combinations of two or more antimalarials to improve microbial killing and reduce further resistance. Propranolol was therefore combined and tested with two widely used antimalarials, chloroquine and artemisinin. IC50 values were first independently determined for each individual drug in P. falciparum 3D7 and/or FCB strains (Figure S2). Using those values, fixed ratios of propranolol:chloroquine (or propranolol:artemisinin) were tested by in vitro hypoxanthine assays [16]. When used in combination against P. falciparum strain 3D7, propranolol reduced the amount of chloroquine required to achieve an IC50 dose by 1 log (Figure 7A and Table S1; the 3:1 and 1:1 propranolol:chloroquine combinations had 11- and 4-fold effects, respectively). Isobologram analysis (Figure S3) indicated that there was an additive antimalarial effect between propranolol and chloroquine. Similar results were found for this combination against the more resistant P. falciparum FCB (Figures 7B and S3). Propranolol did not reverse chloroquine resistance, but did reduce the effective dose in the resistant (FCB) and sensitive (3D7) strains. This result was different than the well-known chloroquine reversal seen in previous fixed-ratio drug combinations using chloroquine and the calcium-channel blocker verapamil [16]. Importantly, this β-blocker did not antagonize chloroquine against either strain, suggesting that blocking Gs function may enable utilization of chloroquine at lower concentrations and thus may facilitate its use against resistant parasites.

Artemisinin is a newer, schizonticidal antimalarial that is gaining acceptance for treatment of severe and uncomplicated malaria because of its rapid action and lower prevalence of resistance [26,27]. Its mode of action is thought to be distinct from that of chloroquine [28]. When used in combination, propranolol also reduced the amount of artemisinin required to achieve an effective dose 5-fold (Figure 7C) and acted in a potent, additive fashion (Figure S3; Table S1). Since propranolol was additive with two distinct drugs, it may be effective when combined with a range of...
existing antimalarials in order to also reduce their required doses.

Our previous results suggested that the requirement for host signaling via β-ARs and Gs was conserved across parasite species. We therefore further tested propranolol-containing drug combinations in the P. berghei ANKA mouse model of malarial infection. When tested alone in mice, the IC50 of racemic propranolol was 7.5 mg/kg/d [7]. As shown in Figures 7D and S3, a combination of 2:1 propranolol:chloroquine reduced the IC50 of chloroquine from 1.64 to 0.66 mg/kg/d. The 1:1 and 1:2 propranolol:chloroquine combinations had less effect. This finding is in contrast to our results in vitro where 1:1 propranolol:chloroquine combinations had a 4-fold effect. This discrepancy may be due to the fact that the half-life of propranolol is 3–4 h [29,30], and therefore multiple treatments and/or more stable compounds may prove more effective. Furthermore, since mice metabolize drugs at higher levels than humans [31,32], mouse-derived data likely overestimate the amount of drug required in humans. Importantly, as in in vitro studies, the combinations tested were not antagonistic (Figure S3). Thus, both our in vitro and in vivo data suggest that targeting erythrocyte Gs in combination with existing antimalarial drugs may have therapeutic potential and may reduce the amount of existing drug needed to effectively treat patients.

**Discussion**

In this paper, we describe the development of erythrocyte "ghosts" active in β-adrenergic signaling that support robust *P. falciparum* growth in culture. With this system, we show that a Gs peptide inhibits activation of erythrocyte β-AR signaling by β-agonists, providing definitive evidence that the peptide targets erythrocyte Gs signaling. At the same pharmacological concentrations, the peptide significantly inhibits malarial invasion of ghosts as well as intracellular maturation of parasites. Furthermore, we find that inhibiting Gs signaling with β-blockers also inhibits intracellular parasite growth. Finally, we show that a β-blocker such as propranolol can be used to reduce doses of existing antimalarials in both in vitro and in vivo infections. We therefore establish that Gs offers a host target to fight infection and to develop new antimalarial chemotherapies.

Erythrocyte ghost preparations have been described previously for studying the erythrocyte membrane and
cytoskeleton and malarial infection [33–38]. However, malarial infection rates of earlier ghosts were either untested or lower than in normal erythrocytes. In contrast, the ghosts described here retained mature erythrocyte double-discoidal morphology, Gs signaling responses, and support of robust malarial infection. Several differences between our procedure and procedures described in prior reports include the lysis of erythrocytes in 3.5-kDa MWCO dialysis membranes rather than in 12–14-kDa MWCO membranes used previously, and our use of a potassium-rich rescaling buffer rather than isotonic saline. Dialysis pore size may be critical since a 10–13-kDa dialyzable, cytoplasmic erythrocyte protein was reported necessary for malarial invasion of ghosts [39,40]. Prior studies did not include GTP, which was incorporated here to ensure the support of a GTP cycle. Ghosts prepared in this manner can be loaded with a variety of peptidic, proteinaceous, fluorescent, or other cargoes and are likely suitable for studying many aspects of erythrocyte function and malarial infection. We have used them to definitively establish that erythrocyte β-adrenergic signaling is indeed mediated by Gs and thus to explain why inhibitors of receptor-mediated Gs signaling (such as propranolol) block malaria parasite invasion and intracellular growth. The findings strongly support the possibility that the erythrocyte Gs pathway might be targeted to treat malaria.

The concept of host-targeted therapies for treating infectious diseases has only emerged recently and, to the best of our knowledge, is unexplored for parasitic infections. Since malaria parasites must invade host cells to proliferate, host pathways necessary for parasite survival present opportunities for intervention. Here we have shown that targeting erythrocyte Gs inhibits parasite growth within erythrocytes as well as at the initial entry event. One obvious possible disadvantage of host-targeted therapy is potential toxicity to the host since Gs regulates many cellular pathways by modulating transcription factors, ion channels, metabolic enzymes, and other molecules [41]. However, Gs signaling alone is insufficient to drive vacuole formation (e.g., vacuoles do not form in isoproterenol-treated erythrocytes), and therefore parasite components are expected to engage this host signaling pathway during invasion [42]. Other parasite proteins may interact with this pathway during intracellular growth. Thus, optimal inhibitors should target interactions between host Gs and parasite proteins, and these may have significantly reduced toxicity, particularly if they can be made additionally selective for erythrocyte Gs. The wide array of pharmacological GPCR-inhibitors currently available suggest chemical backbones that may be useful in rational design of such antimalarials.

In addition, antihypertensive drugs that down-regulate Gs via host receptors (i.e., β-blockers such as the first-generation drug propranolol) are extremely well-tolerated, partly because the host can adapt to drug treatment by producing additional adrenergic receptors and Gs. Since the mature erythrocyte is incapable of de novo protein synthesis, it cannot mount such an adaptive response. Thus, erythrocytes may be more vulnerable to inhibition of β-AR/Gs signaling, while other host tissues could adapt to avoid toxicity. A well-developed, host-targeted antimicrobial therapy directed at human chemokine receptor 5 (CCR5) for the treatment of drug-resistant HIV is currently in clinical trials. Short-term treatment with CCR5 antagonists reduced viral loads in infected patients [43], providing proof of concept for targeting a host determinant to treat a major infectious disease.

Malaria is a major threat to global health, and there is an imperative to use existing drugs to treat patients while the search for vaccines and better drugs continues. Development of a new drug is expensive and can take more than a decade [44]. Propranolol and a wide range of β-blockers are currently approved for human use. In humans, racemic propranolol is typically prescribed at ~60–320 mg/d (~0.8–4.5 mg/kg/d in an average 70-kg person) [45] with a maximum clinical dose of ~10 mg/kg/d. The maximum concentration of propranolol in blood approaches 1 μM [29], and thus it is likely that treatments can be designed that achieve IC50s in the bloodstream (0.4–1.2 μM in the work discussed in this paper; 0.4 μM, Drug Screening Program, Strategic and Discovery Research UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases, personal communication) using a range of dosages comparable to those used for hypertension. Furthermore, higher concentrations of the drug can also be administered [45].

Malaria patients may be hypotensive [46], and therefore treatment with β-blockers must be considered carefully. However, at normal dosages, propranolol does not usually cause orthostatic hypotension because the β-adrenergic system maintains peripheral vasoconstriction [47,48]; some patients may show mild orthostatic hypotension [49]. Other quinoline antimalarials (e.g., quinine and mefloquine) may also exacerbate orthostatic hypotension in malaria patients [46,50]. The main cause of hypotension in malaria patients is acidosis secondary to hypovolemia, which can be managed with intravenous saline. Propranolol has been found to mitigate some hyper-adrenergic effects that occur in patients with shock secondary to hypovolemia. In such cases, β-adrenergic blockade by propranolol is thought to reduce muscle lactate production and to limit metabolic acidosis [51,52]. Thus, this drug may have unseen benefits for clinically ill patients.

As with any new drug, care would obviously need to be taken in any clinical malaria study using propranolol-containing combinations. Propranolol is contraindicated for use with the quinoline antimalarial quinidine [47], which also has β-adrenergic–blocking activities [53]. Other quinolone antimalarials (e.g., quinine and mefloquine) that exacerbate orthostatic hypotension also produce electrocardiographic abnormalities (i.e., long corrected QT interval), although not of the severity seen with halofantrine [54]. There is one report of a patient with a previous myocardial infarction who was taking propranolol and suffered a cardiorespiratory arrest 5 h after taking a single dose of mefloquine; the patient made a full recovery [55]. Mefloquine and propranolol are also associated independently with depression. Thus, some quinolines may be contraindicated for use with propranolol. However, only minor, asymptomatic corrected QT interval disturbances are found with other antimalarial drugs such as chloroquine (a quinoline) [56], sulfadoxine-pyrimethamine [57], and artemisinin [58]; no electrocardiographic changes were associated with atovaquone-proguanil alone or in combination with artemisinin [59]. Overall, propranolol has few serious side effects, is recommended for use in pregnant women, is widely approved by regulatory agencies, and is frequently taken for life.
In addition to its safety and efficacy, propranolol is made even more attractive by its low off-patent cost, high stability, and ease of production. In addition, second- and third-generation β-blockers have been developed, and all generations of β-blockers are routinely taken for many years to treat chronic conditions. Thus, it may be an appropriate time to evaluate combinations containing β-blockers to treat human clinical infections that fail to respond to optimized antimalarial therapy.

Supporting Information

Figure S1. G<sub>i</sub> and G<sub>q</sub> Specific Peptides Do Not Inhibit Malarial Invasion of Ghosts

Erythrocyte ghosts were incubated with 50 µM control G<sub>i</sub>, G<sub>i</sub>, G<sub>i</sub>, or G<sub>q</sub> peptides and tested for invasion as described in Methods. Error bars show standard deviations across three experiments in triplicate. Found at doi:10.1371/journal.pmed.0030528.s001 (52 KB PPT).

Figure S2. [3H]-Hypoxanthine Assays to Determine In Vitro IC<sub>50</sub> Values of Individual Drugs Used in This Study

IC<sub>50</sub> for each drug were determined in chloroquine-sensitive (3D7) and chloroquine-resistant (FCB) P. falciparum by in vitro [3H]-hypoxanthine incorporation (see Methods). IC<sub>50</sub> values were determined by fitting the data as described in Methods; each data point is shown in triplicate. Asterisks denote p < 0.05; hash marks denote p < 0.01; crosses denote p < 0.001. CQ, chloroquine; Art, artemisinin; Prop, propranolol.

Figure S3. Propranolol Functions Additively with Existing Antimalarials In Vitro and In Vivo

Isobolograms (see Methods) are presented for in vitro studies of propranolol and chloroquine ([A], in 3D7 strain; [B], in FCB strain) and propranolol and artemisinin ([C], in 3D7 strain), and an in vivo study of propranolol and chloroquine in the P. berghei ANKA mouse model of malarial infection (D).

Table S1. Effects of Propranolol-Containing Drug Combinations on Growth of P. falciparum and P. berghei

Table S2. Accession Numbers

The SwissProt (http://www.ebi.ac.uk/swissprot) accession numbers for the proteins discussed in this paper are human β<sub>2</sub>-AR (P07550); human heterotrimeric G<sub>i</sub> (P63096); human heterotrimeric G<sub>j</sub> (P29992); human heterotrimeric G<sub>q</sub> (P63092); and PHPRPII (P09582).

Acknowledgments

We thank Drs. Joseph Hoffman, Theodore Steck, and Walter Gratzier for their insightful comments about the production of erythrocyte ghosts.

Author contributions. SCM and KH designed the study, SCM developed the ghosting protocol, performed the in vitro signaling and invasion and growth assays, assessed maturation defects, and did statistical analyses. SCM and TH carried out the in vitro and in vivo drug testing. SCM, JWL, and KH wrote the manuscript. HEH, JWL, and NM provided expertise on signaling and erythrocyte biology.

References

1. Varmus H, Klausner R, Zerhouni E, Acharya T, Daar AS, et al. (2003) Grand challenges in global health. Science 302: 398–399.
2. Miller LH, Baruch DI, Marsh K, Dounko OB (2002) The pathogenic basis of malaria. Nature 415: 673–679.
3. Murphy SC, Miller NL, Harrison T, Lomasney JW, Mohandas N, et al. (2006) Lipid rafts and malaria parasite infection of erythrocytes. Mol Membr Biol 23: 81–88.
4. Murphy SC, Samuel BU, Harrison T, Speicher KD, Speicher DW, et al. (2004) Erythrocyte detergent-resistant membrane proteins: Their characterization and selective uptake during malarial infection. Blood 103: 1920–1926.
5. Samuel BU, Mohandas N, Harrison T, McManus H, Rosse W, et al. (2001) The role of cholesterol and glycosylphosphatidylinositol-anchored proteins of erythrocyte rafts in regulating raft protein content and malarial infection. J Biol Chem 276: 29319–29329.
6. Lauer S, VanVye J, Harrison T, McManus H, Samuel BU, et al. (2000) Vascular uptake of host components, and a role for cholesterol and sphingomyelin in malarial infection. EMBO J 19: 3556–3564.
7. Harrison T, Samuel BU, Akompong T, Hamm M, Mohandas N, et al. (2003) Erythrocyte G protein-co coupled receptor signaling in malarial infection. Science 301: 1734–1736.
8. Eldemondo H, Bangs J, Haldar K (1992) Synthesis and secretion of erythrocyte GS and Malarial Infection

Erythrocyte GS and Malarial Infection

PLoS Medicine | www.plosmedicine.org December 2006 | Volume 3 | Issue 12 | e528
functional studies of interaction between Plasmodium falciparum knob-associated histidine-rich protein (KAHRP) and erythrocyte spectrin. J Biol Chem 280: 31166–31171.

38. Gutiérrez Millán C, Zarazuelo Castaneda A, Sayalero Marinero ML, Lanao JM (2002) Resealed red blood cells and immunity to Plasmodium falciparum in malaria volunteers. Br J Clin Pharmacol 52: 659–662.

39. Mansor SM, Taylor TE, McGrath CS, Edwards G, Ward SA, et al. (1999) The safety and kinetics of intramuscular quinine in Malawian children with moderately severe falciparum malaria. Trans R Soc Trop Med Hyg 83: 482–487.

40. Salomé NJ, Akompong T, Morrow JS, Holder AA, Haldar K (2003) Factors associated with the performance of carrier erythrocytes in the transmission of malaria. Mol Biochem Parasitol 9: 145–160.

41. Neves SR, Ram PT, Iyeran G (2002) G protein pathways. Science 296: 1636–1639.

42. Hiller NL, Akompong T, Morrow JS, Holder AA, Haldar K (2003) Identification of a stomatin orthologue in vacuoles induced in human erythrocytes by malaria parasites. A role for microbial raft proteins in apicomplexan vacuole biogenesis. J Biol Chem 278: 48413–48421.

43. Fatkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, et al. (2005) Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 11: 1170–1172.

44. Dickson M, Gagnon JP (2004) Key factors in the rising cost of new drug discovery and development. Nat Rev Drug Disc 3: 417–429.

45. Beers MH, Berkow Reditors (2006) The Merck manual of diagnosis and therapy. 18th edition. Rahway, New Jersey: Merck Research Laboratories. Available at http://www.merck.com/media/mmpp/pdf/Table_071-6.pdf. Accessed 25 November 2006.

46. Supanaranond W, Davis TM, Pukrittayakamee S, Nagachinta B, White NJ (1996) Identification of a stomatin orthologue in vacuoles induced in human erythrocytes by malaria parasites. The effects of antimalarial drugs. Eur J Clin Pharmacol 44: 325–329.

47. Loon WR, Wilcox CS, Folger W (1986) Orthostatic hypotension due to propranolol and pindolol in healthy volunteers. Br J Clin Pharmacol 20: 459–462.

48. Touze JE, Heno P, Fourcade L, Deharo JC, Thomas G, et al. (2002) The effects of antimalarial drugs on ventricular repolarization. Am J Trop Med Hyg 67: 54–60.

49. O’Connor PC, Finch MJ, Harron DW, Meredith PA, McDevitt DG, et al. (1985) Comparison of the haemodynamic effects of bucindolol, propranolol and propranolol bucindolol in healthy volunteers. Br J Clin Pharmacol 20: 659–662.

50. Mansor SM, Taylor TE, McGrath CS, Edwards G, Ward SA, et al. (1999) The safety and kinetics of intramuscular quinine in Malawian children with moderately severe falciparum malaria. Trans R Soc Trop Med Hyg 83: 482–487.

51. Halmagyi DF, Gillett BJ, Irving MH (1967) Partial and “complete” adrenergic blockade in posthemorrhagic shock. J Appl Physiol 22: 487–494.

52. Luchetta FA, Robinson BR, Friend LA, McCarter F, Frame SB, et al. (1999) Adrenergic antagonists reduce lactic acidosis in response to hemorrhagic shock. J Trauma 47: 873–875.

53. Motulsky HJ, Maisel AS, Snively MD, Insel PA (1984) Quinidine is a competitive antagonist at alpha-1- and alpha-2-adrenergic receptors. Circ Res 55: 376–381.

54. Touze JE, Heno P, Fourcade L, Deharo JC, Thomas G, et al. (2002) The effects of antimalarial drugs on ventricular repolarization. Am J Trop Med Hyg 67: 54–60.

55. [No authors listed.] (1990) Melofloxine for malaria. Med Lett Drugs Ther 31: 13–14.

56. Gustos MD, Gay F, Diouet B, Thomare P, Warot D (1994) The pharmacokinetics and electrophotocardiographic effects of chloroquine in healthy subjects. Trop Med Parasitol 45: 83–86.

57. Ngouesse B, Basco LK, Kingwal P, Keundjian A, Blackett KN (2000) Cardiac effects of amiodarone and sulfadiazine-pyrimethamine in malaria-infected African patients. Am J Trop Med Hyg 63: 711–716.

58. Ribeiro IR, Olliaro P (1998) Safety of artesinin and its derivatives. A review of published and unpublished clinical trials. Med Trop (Trop) 58: 50–53.

59. Gupta RK, Van Vugt M, Paiphun L, Slight T, Looareesuwan S, et al. (2005) Short report: No evidence of cardio toxicity of atovaquone-proguanil alone or in combination with artesunate. Am J Trop Med Hyg 73: 267–268.

Editors’ Summary

Background. New drugs for treatment of malaria are urgently needed, because the malaria parasite has evolved resistance against virtually all types of commonly used drugs. When a person is bitten by a malaria-infected mosquito, the parasite first infects the person’s liver cells before going on to infect red blood cells, where the parasites multiply and develop into a parasite stage called a schizont. The red blood cells then burst and release more schizonts into the bloodstream; it is this “blood stage” of infection in humans that causes the symptoms of disease. Therefore efforts to develop new drugs against malaria often focus on this “blood stage” of infection. One strategy for developing new drugs is termed the “host-targeted” approach. This means that rather than trying to block processes occurring within the parasite itself, a drug can be developed which blocks processes within the person’s red blood cells, and which would therefore be needed by the parasite to complete its life cycle. It will be difficult for malaria parasites to evolve resistance to such a drug, because changes in a person’s red blood cells occur much more slowly than in the parasites themselves.

Why Was This Study Done? This research group has been studying a set of molecular processes within human red blood cells which seemed to be required for entry of malaria parasites into the cells. They wanted to get a better understanding of those processes and, specifically, to find out whether it would be possible to use particular molecules to block those processes, and by doing so to prevent malaria parasites from entering and multiplying within red blood cells. In particular, when the malaria parasites invade the red blood cell, they form membranes around the red blood cell, containing lipids and proteins “hijacked” from the red blood cell membrane. These researchers already knew that two particular proteins were hijacked in this way: the β2-adrenergic receptor (β2-AR) and heterotrimeric G protein (G). These two proteins act together to pass messages across the surface of the membrane to the inside of the cell. Small molecules could be used to block signaling through β2-AR and G, and therefore potentially to provide a new way of preventing malaria parasites from entering red blood cells and multiplying within them.

What Did the Researchers Do and Find? Firstly, the researchers made red blood cell “ghosts” in which to study these molecular processes. This meant that they took fresh red blood cells from healthy human volunteers, burst them to remove half the contents and loaded them with markers and other cargo before resealing the membranes of the cell. These resealed markers and cargo allowed them to see what was happening inside the cells. Malaria parasites were able to invade these ghosts normally and multiply within them. When the researchers introduced a specific peptide (a molecule consisting of a short series of amino acids), they found that it blocked G signaling within the ghosts. This peptide also prevented malaria parasites from developing inside the ghosts. Therefore, they concluded that G signaling inside the red blood cell was important for the parasite life cycle. The researchers then examined a drug called propranolol which is already known to act on G, signaling and which is commonly prescribed for high blood pressure. This drug also blocked development of malaria parasites inside the ghosts when used at a particular concentration. Finally, the researchers studied the effect of giving propranolol, along with other antimalarial drugs, to human malaria parasites in a culture dish and to mice infected with a malaria parasite that infects rodents. In these experiments, adding propranolol reduced the amount of other “parasite-targeted” control in cells needed to effectively treat malarial infection in tissue culture and in mice.

What Do These Findings Mean? Showing that the G signaling pathway is important for the malaria parasite’s life cycle opens up new possibilities for drug development. Specifically, propranolol (which is already approved for treatment of high blood pressure and other conditions) might itself provide a new candidate therapy, either alone or in combination with existing drugs. These combinations would first, however, need to be tested in human clinical trials, perhaps by seeing whether they have antimalarial activity in people who have not responded to existing antimalarial drugs. Since it acts to lower blood pressure, which can already be low in some people with malaria, there are some concerns that propranolol might not be a suitable drug candidate. Interestingly, existing antimalarial drugs that also reduce blood pressure. However, other molecules which block G signaling could be tested for activity against malaria should propranolol prove not to be an ideal drug candidate.

Additional Information. Please access these Web sites via the online version of this summary at http://dx.doi.org/10.1371/journal.pmed.0030528.

The World Health Organization publishes a minisite containing links to information about all aspects of malaria worldwide, including treatment, prevention, and current programs for malaria control. Medicines for Malaria Venture is a collaboration between public and private organizations (including the pharmaceutical industry) that aims to fund and manage the development of new drugs for treatment and prevention of malaria. Wikipedia entries for drug discovery and drug development (Wikipedia is an internet encyclopedia that anyone can edit)